Drugs / SQZ-PBMC-HPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04084951 | Jan 2020 → Feb 2023 | — | SQZ Biotechnologies | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQZ-PBMC-HPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04084951 ↗ |
| Modality | Cell therapy | “antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16” NCT04084951 ↗ |